We are a clinical-stage biopharmaceutical company developing immune engagers to treat autoimmune, fibrosis, oncologic, and neuro-inflammatory diseases.
Congrats to our sister company Skyhawk for their exciting new data on lowering mutant huntingtin protein in Huntington's patients! https://t.co/5zHZMF3UDF
Dear Dfly friends and colleagues - In honor of BIO Boston next Tuesday June 17th we are hosting a special private screening of Bill Haney's new film, Cracking the Code: Phil Sharp and the Biotech Revolution, at Boston's ICA: RSVP here! https://t.co/AQRP5g0CXn
Excited for our sister company @Skyhawk_Tx that presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic. #hdyocongress
Wonderful event! Thank you @JohnCendpts for joining us and doing the Q&A with Bill Haney, our CEO and movie maker, about Bill's new documentary featuring the amazing Phil Sharp @kochinstitute@MIT.
@JohnCendpts John - thank you for doing the Q&A ... going to be fun. Name of film is "Cracking the Code - Phil Sharp and the RNA Revolution" - cheers all
When Bill Haney asked to turn the microphone around and film me for his new documentary on Nobel winner Phil Sharp, who was present at the creation of the biotech industry, I quickly reassured him that I’d be certain to be a massive disappointment. Haney, though, is a persistent enthusiast and barreled ahead. Bill and I will be taking the stage after a screening of his new biodoc in San Francisco January 12 — Sunday afternoon — at 4 pm Pacific at the Yerba Buena Center for the Arts, 700 Howard Street, for a discussion. If you’d like to join us, and there’s no charge, please RSVP to [email protected].
Dragonfly Therapeutics is presenting 2 posters, today, at the Society for #Immunotherapy of #Cancer Annual Conference! Swing by during the poster session and learn more #SITC24 https://t.co/8i1eVLgZlJ
Thank you to our Corporate Sponsors and all our individual donors who helped break records at The CheckPoints: Rockin' for a Cure fundraiser! Because of this generosity, SITC’s Forward Fund will award 39 abstract travel awards to early career scientists at #SITC24!
Come check out our poster presentation (# 165b) with Dr. Carneiro @BrownUCancer on our Phase 1/1b, First-in-Human, multi-part study of DF6215, an engineered IL-2Rα-active agonist for advanced solid tumors, in the Developmental Therapeutics-Immunotherapy poster session! #ASCO24
We have entered into a clinical collaboration with @Merck to evaluate DF9001, our EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors expressing EGFR. https://t.co/apkcKkBOW1
Congratulations to all the new AACR Fellows, so many inspiring friends & scientists! Incl. Jacks lab alum @AttardiLaura, @kochinstitute’s @snbhatia, Ben Ebert (who I shared TC space w/ in grad school!), @dragonflytx MAB chair @PamSharmaMDPhD, Pasi Yanne & Tim Rebbeck